S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PMVP · PMV Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
PMV Pharmaceuticals Inc (PMVP)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$1.36
-0.04
(-2.86%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.36
$1.35
$1.41
52-WEEK RANGE
$1.36
$1.02
$1.91
What's happening
- PMVP is down 2.86% today, trading at $1.36. — Live quote
- Volume today (15,085) is well below its 3-month average of 567,200. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.34 actual vs. $-0.40 estimated (+14.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 7
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PMVP
+11.20%
vs S&P 500
-1.58%
1-YEAR RETURN
PMVP
-5.44%
vs S&P 500
-20.00%
6-MONTH RETURN
PMVP
+1.46%
3-MONTH RETURN
PMVP
+6.11%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.34
Est. $-0.40
BEAT +14.0%
2026-04-26 (Q1 2026)
$-0.34
Est. $-0.42
BEAT +18.7%
2026-01-26 (Q4 2025)
$-0.34
Est. $-0.41
BEAT +17.7%
2025-10-26 (Q3 2025)
$-0.40
Est. $-0.41
BEAT +2.6%
Valuation Measures & Ratios
Enterprise Value4$90.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book71.00
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-78.11%
Return on Assets (ROA9)-70.13%
Avg Volume (3M)567,200
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $70.7M | $65.3M | $73.4M | $55.4M | $56.9M |
| P/E | -0.90 | -0.84 | -0.93 | -0.94 | -1.07 |
| Price/Book | 0.99 | 0.74 | 0.61 | 0.39 | 0.36 |
| ROE | -109.64% | -88.38% | -65.23% | -42.02% | -33.19% |
| ROA | -95.52% | -80.51% | -58.97% | -38.65% | -31.15% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,794,327
Change from Prior Settlement-4.28%
% of Float—
Days to Cover (Short Ratio)3.59
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-05; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -5.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PMVP
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$18.9M | -$19.0M | -$22.5M | -$22.9M | -$21.6M | -$21.9M | -$20.2M | -$18.2M |
| Net income | -$18.1M | -$18.0M | -$21.1M | -$21.2M | -$17.4M | -$19.2M | -$1.2M | -$15.3M |
| EPS (diluted) | $-0.34 | $-0.34 | $-0.40 | $-0.41 | $-0.34 | $-0.37 | $-0.02 | $-0.30 |
| EPS (basic) | $-0.34 | $-0.34 | $-0.40 | $-0.41 | $-0.34 | $-0.37 | $-0.02 | $-0.30 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $82.1M | $96.6M | $116.6M | $133.8M | $152.9M | $170.6M | $191.3M | $223.5M |
| Total liabilities | $10.6M | $8.6M | $11.8M | $12.8M | $12.2M | $10.5M | $15.2M | $25.6M |
| Stockholders' equity | $71.5M | $88.0M | $104.7M | $121.0M | $140.6M | $160.1M | $176.1M | $197.9M |
| Total current assets | $81.4M | $95.8M | $115.2M | $132.4M | $145.3M | $163.5M | $175.7M | $189.6M |
| Total current liabilities | $10.6M | $8.6M | $11.4M | $12.3M | $11.6M | $9.8M | $14.4M | $13.6M |
| Cash & equivalents | $12.5M | $39.1M | $38.0M | $36.3M | $44.1M | $51.3M | $40.9M | $48.8M |
| Marketable securities (current) | $67.0M | $54.4M | $75.0M | $92.9M | $98.1M | $109.0M | $128.6M | $134.0M |
| Marketable securities (non-current) | $0 | $0 | $0 | $0 | $6.0M | $5.4M | $13.8M | $15.1M |
| Property, plant & equipment | $154.0K | $203.0K | $237.0K | $255.0K | $287.0K | $376.0K | $409.0K | $10.1M |
| Other non-current assets | $296.0K | $296.0K | $297.0K | $249.0K | $248.0K | $237.0K | $235.0K | $242.0K |
| Accounts payable | $2.0M | $1.6M | $3.2M | $3.4M | $2.6M | $3.6M | $6.6M | $2.1M |
| Accrued liabilities | $8.3M | $6.7M | $7.9M | $8.5M | $8.6M | $5.8M | $7.4M | $10.3M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Retained earnings | -$482.6M | -$464.5M | -$446.5M | -$428.4M | -$407.4M | -$386.1M | -$368.7M | -$345.7M |
| Accumulated other comprehensive income (loss) | -$82.0K | -$15.0K | $84.0K | $91.0K | $21.0K | $84.0K | $139.0K | $410.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.6M | -$19.7M | -$17.2M | -$19.8M | -$18.3M | -$18.3M | -$16.7M | -$16.8M |
| Investing cash flow | -$12.2M | $20.8M | $18.4M | $12.0M | $11.0M | $28.7M | $7.7M | $17.1M |
| Financing cash flow | $143.0K | $0 | $392.0K | $0 | $103.0K | $10.0K | $172.0K | $0 |
| Free cash flow | -$14.6M | -$19.7M | -$17.2M | -$19.8M | -$18.3M | -$18.3M | -$16.7M | -$16.8M |
| Capital expenditures | $0 | $0 | $15.0K | -$1.0K | $11.0K | $4.0K | $56.0K | $1.0K |
| Share-based compensation | $1.5M | $1.4M | $1.4M | $1.4M | $1.7M | $1.5M | $1.3M | $2.2M |
| Change in accounts payable | $389.0K | -$1.5M | -$244.0K | $801.0K | -$995.0K | -$3.0M | $4.5M | -$2.5M |
| Purchases of investments | $26.7M | $10.7M | $21.0M | $20.5M | $31.0M | $15.7M | $37.5M | $39.4M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$86.2M | -$85.4M | -$80.1M | -$77.0M | -$58.3M |
| Net income | -$77.7M | -$58.7M | -$69.0M | -$73.3M | -$57.8M |
| EPS (diluted) | $-1.48 | $-1.14 | $-1.44 | $-1.61 | $-1.28 |
| EPS (basic) | $-1.48 | $-1.14 | $-1.44 | $-1.61 | $-1.28 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $116.6M | $191.3M | $252.2M | $270.3M | $331.6M |
| Total liabilities | $11.8M | $15.2M | $26.5M | $24.3M | $23.0M |
| Stockholders' equity | $104.7M | $176.1M | $225.7M | $246.0M | $308.6M |
| Total current assets | $115.2M | $175.7M | $207.4M | $247.0M | $301.3M |
| Total current liabilities | $11.4M | $14.4M | $14.0M | $10.8M | $12.2M |
| Cash & equivalents | $38.0M | $40.9M | $37.7M | $108.3M | $172.5M |
| Marketable securities (current) | $75.0M | $128.6M | $165.4M | $132.8M | $124.7M |
| Marketable securities (non-current) | $0 | $13.8M | $25.5M | $2.5M | $16.9M |
| Property, plant & equipment | $237.0K | $409.0K | $10.7M | $11.0M | $3.1M |
| Other non-current assets | $297.0K | $235.0K | $190.0K | $313.0K | $221.0K |
| Accounts payable | $3.2M | $6.6M | $3.2M | $3.0M | $3.2M |
| Accrued liabilities | $7.9M | $7.4M | $9.9M | $7.3M | $8.6M |
| Other non-current liabilities | — | — | — | — | — |
| Retained earnings | -$446.5M | -$368.7M | -$310.0M | -$241.0M | -$167.7M |
| Accumulated other comprehensive income (loss) | $84.0K | $139.0K | $224.0K | -$445.0K | -$78.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$73.6M | -$51.3M | -$55.7M | -$63.8M | -$46.6M |
| Investing cash flow | $70.2M | $53.4M | -$50.5M | -$1.4M | -$143.6M |
| Financing cash flow | $505.0K | $313.0K | $35.6M | $958.0K | $2.0M |
| Free cash flow | -$73.6M | -$51.9M | -$56.6M | -$71.7M | -$47.9M |
| Capital expenditures | $29.0K | $655.0K | $962.0K | $8.0M | $1.3M |
| Share-based compensation | $5.9M | $8.9M | $12.4M | $10.2M | $5.3M |
| Change in accounts payable | -$3.4M | $3.3M | $235.0K | -$389.0K | $191.0K |
| Purchases of investments | $88.2M | $148.3M | $220.5M | $229.2M | $256.8M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PMVP as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers62.5%
Shares Outstanding53,460,432
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 5,330,000 | $7.1M | 9.97% | +0.2% | 2026-08-07 |
| TANG CAPITAL MANAGEMENT LLC | 4,245,085 | $5.7M | 7.94% | +0.0% | 2026-08-14 |
| Sio Capital Management, LLC | 2,634,137 | $3.5M | 4.93% | -14.4% | 2026-07-15 |
| Euclidean Capital LLC | 2,627,643 | $3.5M | 4.92% | +0.0% | 2026-08-14 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,360,000 | $3.2M | 4.41% | +26.9% | 2026-08-14 |
| ACADIAN ASSET MANAGEMENT LLC | 2,215,894 | $3.0K | 4.14% | +0.0% | 2026-08-12 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,012,020 | $2.7M | 3.76% | +1.9% | 2026-06-30 |
| ArrowMark Colorado Holdings LLC | 1,959,579 | $2.6M | 3.67% | -31.8% | 2026-08-13 |
| TWO SIGMA INVESTMENTS, LP | 1,954,136 | $2.6M | 3.66% | +3.7% | 2026-08-07 |
| Eversept Partners, LP | 1,890,904 | $2.5M | 3.54% | -19.5% | 2026-08-14 |
| BlackRock, Inc. | 919,818 | $1.2M | 1.72% | +5.2% | 2026-08-07 |
| Stonepine Capital Management, LLC | 536,086 | $718.4K | 1.00% | -24.3% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 473,158 | $634.6K | 0.89% | -4.6% | 2026-08-12 |
| Aldebaran Capital, LLC | 467,432 | $626.4K | 0.87% | -1.3% | 2026-08-13 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 428,853 | $574.7K | 0.80% | +0.0% | 2026-08-14 |
| BIT Capital GmbH | 407,555 | $546.1K | 0.76% | +229.9% | 2026-08-12 |
| Verdad Advisers, LP | 362,361 | $485.6K | 0.68% | +101.1% | 2026-08-14 |
| Walleye Capital LLC | 335,694 | $449.8K | 0.63% | +0.0% | 2026-07-30 |
| Assenagon Asset Management S.A. | 330,003 | $442.2K | 0.62% | -8.5% | 2026-07-08 |
| MARSHALL WACE, LLP | 321,610 | $431.0K | 0.60% | -25.9% | 2026-08-13 |
| VANGUARD FIDUCIARY TRUST CO | 254,775 | $341.4K | 0.48% | -14.5% | 2026-06-30 |
| Bank Of America Corp /De/ | 240,110 | $321.7K | 0.45% | -0.2% | 2026-08-14 |
| ADAR1 Capital Management, LLC | 201,008 | $269.4K | 0.38% | -13.0% | 2026-08-14 |
| State Street Corp | 183,178 | $245.5K | 0.34% | +0.0% | 2026-08-07 |
| RBF Capital, LLC | 162,200 | $217.3K | 0.30% | +0.0% | 2026-08-06 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-07-01 to 2025-10-27
Recent transactions
- Most recent: Mack David Henry (President and CEO) — Option exercise of 220,643 shares on 2025-10-27.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Mack David Henry | President and CEO | Option exercise | 2025-10-27 | 220,643 |
| ORBIMED ADVISORS LLC | 10% owner | Open market sale | 2025-10-23 | 1,000,000 |
| Ticktin Robert | General Counsel & COO | Open market sale | 2025-07-01 | 23,151 |
| Jalota Deepika | Chief Development Officer | Open market sale | 2025-07-01 | 33,065 |
| Carulli Michael | Chief Financial Officer | Open market sale | 2025-07-01 | 28,249 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-10-27 | Mack David Henry | President and CEO | Option exercise | 220,643 | $1.37 |
| 2025-10-23 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 1,000,000 | $1.52 |
| 2025-09-10 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 500,000 | $1.80 |
| 2025-07-01 | Ticktin Robert | General Counsel & COO | Open market sale | 23,151 | $1.06 |
| 2025-07-01 | Jalota Deepika | Chief Development Officer | Open market sale | 33,065 | $1.06 |
| 2025-07-01 | Carulli Michael | Chief Financial Officer | Open market sale | 28,249 | $1.06 |
| 2025-07-01 | Mack David Henry | President and CEO | Open market sale | 58,411 | $1.06 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:26 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-05 | 8-K | 2026-10-01 | View on SEC.gov → |
| 2026-09-02 | 8-K | 2026-08-31 | View on SEC.gov → |
| 2026-08-31 | 8-K | 2026-08-31 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 8-K | 2026-06-04 | View on SEC.gov → |
Recent news
Headlines about PMVP (PMV Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
PMV appoints Matt Eckler to board: 2027 filing plans matter for PMV Pharmaceuticals stock
AD HOC NEWS · 2026-10-21 -
PMV appoints Matt Eckler: what the 2027 filing means for PMV Pharmaceuticals stock - ad-hoc-news.de
ad-hoc-news.de · 2026-10-16 -
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
Yahoo · 2026-10-12 -
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity
Seeking Alpha · 2026-10-07 -
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
Yahoo Finance · 2026-10-05 -
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
Yahoo Finance · 2026-09-08 -
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
Yahoo Finance · 2026-09-01 -
PMV Pharma prices $50M IPO at $1.21 per share
Seeking Alpha · 2026-09-01
No headlines in this category right now — try “All”.